作者
Neda Roshanravan, Samad Ghaffari, Mehdi Hedayati
发表日期
2020/7/1
期刊
Diabetes & Metabolic Syndrome: Clinical Research & Reviews
卷号
14
期号
4
页码范围
637-639
出版商
Elsevier
简介
The pandemic of coronavirus disease 2019 (COVID-19) is a global health emergency that poses a significant threat to world people’s health. This outbreak causes major challenges to healthcare systems. Given the lack of effective treatments or vaccine for it, the identification of novel and safe drugs against COVID-19 infection is an urgent need. Angiotensin-converting enzyme 2 (ACE2) is not only an entry receptor of the SARS-CoV-2 virus, the virus that causes COVID-19, but also can protect from lung injury. In this view, we highlighted potential approaches to address ACE2-mediated SARS-CoV-2 virus, including 1) delivering an excessive soluble form of ACE2 (recombinant human ACE2: rhACE2) and 2) inhibition of the interaction between SARS-CoV-2 virus and ACE2 by some compounds with competitive effects (morphine and codeine). Further clinical trials in this regard can reveal a more definite conclusion …
引用总数
2020202120222023202410277122
学术搜索中的文章
N Roshanravan, S Ghaffari, M Hedayati - Diabetes & Metabolic Syndrome: Clinical Research & …, 2020